Reply to 'The challenge to one course carboplatin in seminoma clinical stage 1' by Dieckmann and Anheuser

Affiliations

¹ The Cancer Clinic, St Olavs Hospital, Trondheim, Norway torgrim.tandstad@stolav.no.
² Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

Free article

Comment

T Tandstad et al. Ann Oncol. 2016 Sep.

Free article

. 2016 Sep;27(9):1809.

doi: 10.1093/annonc/mdw207. Epub 2016 May 13.

¹ The Cancer Clinic, St Olavs Hospital, Trondheim, Norway torgrim.tandstad@stolav.no.
² Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

No abstract available

Comment on

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Ann Oncol. 2016 Jul;27(7):1299-304. doi: 10.1093/annonc/mdw164. Epub 2016 Apr 6. Ann Oncol. 2016. PMID: 27052649
The challenge to one-course carboplatin in seminoma clinical stage 1.
Dieckmann KP, Anheuser P. Dieckmann KP, et al. Ann Oncol. 2016 Aug;27(8):1648-9. doi: 10.1093/annonc/mdw187. Epub 2016 May 6. Ann Oncol. 2016. PMID: 27154420 No abstract available.